W hen BioNTech agreed to acquire rival messenger RNA company CureVac in a $1.25 billion stock deal earlier this summer, some ...

Discover key insights from Roivant Sciences' Q1 2025 earnings call, including brepocitinib DM data milestones, financial strength, and strategic ...

Kennedy is vowing to "fix" the federal program for compensating Americans injured by vaccines, opening the door to sweeping changes for a system long targeted by anti-vaccine activists.

This episode of Pharma Pulse explores the FDA’s new proactive quality review initiative for drug manufacturing, GSK’s $370 ...

GSK (NYSE:GSK) announced Monday that the U.S. Food and Drug Administration has accepted its priority review application for ...

Adams warns cutting funding for mRNA vaccine research will cost lives, derail medical progress, and give China an advantage.

GSK (NYSE:GSK) (LON:GSK) said on Monday that the U.S. Food and Drug Administration has accepted its priority review ...

CureVac ( (CVAC)) has provided an announcement. On August 7, 2025, CureVac announced the resolution of U.S. patent litigation with Pfizer/BioNTech concerning mRNA-based COVID-19 vaccines. As part of ...

Are women somehow missing from the future of innovation? New research suggests that gender bias may be quietly shaping the ...